{
    "root": "a0edcebe-af2d-463c-aad8-fa5fb77f0828",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Sertraline hydrochloride",
    "value": "20240915",
    "ingredients": [
        {
            "name": "SERTRALINE HYDROCHLORIDE",
            "code": "UTI8907Y6X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9124"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX",
            "drugbank_id": "https://go.drugbank.com/drugs/DB09462"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "MENTHOL, UNSPECIFIED FORM",
            "code": "L7T10EIP3A"
        },
        {
            "name": "BUTYLATED HYDROXYTOLUENE",
            "code": "1P9D0Z171K",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_24751"
        }
    ],
    "indications": {
        "text": "sertraline hydrochloride oral solution indicated treatment following [ ( 14 ) ] : \u2022major depressive disorder ( mdd ) \u2022obsessive-compulsive disorder ( ocd ) \u2022panic disorder ( pd ) \u2022posttraumatic stress disorder ( ptsd ) \u2022social anxiety disorder ( sad ) \u2022premenstrual dysphoric disorder ( pmdd )",
        "doid_entities": [
            {
                "text": "depressive disorder (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            },
            {
                "text": "ocd (DOID:84)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_84"
            },
            {
                "text": "ptsd (DOID:2055)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2055"
            },
            {
                "text": "anxiety (DOID:2030)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2030"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "obsessive-compulsive disorder",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_C052"
            }
        ]
    },
    "contraindications": {
        "text": "indication starting maximum mdd ( 2.1 ) 50 mg per day 200 mg per day ocd ( 2.1 ) 25 mg per day ( ages 6-12 ) 50 mg per day ( ages \u2265 13 ) 200 mg per day pd , ptsd , sad ( 2.1 ) 25 mg per day 200 mg per day pmdd ( 2.2 ) continuous dosing 50 mg per day 150 mg per day pmdd ( 2.2 ) intermittent dosing 50 mg per day luteal phase 100 mg per day luteal phase \u2022 inadequate response starting , titrate 25-50 mg per day increments weekly mdd , ocd , pd , ptsd , sad ( 2.1 ) \u2022 full prescribing information titration pmdd ( 2.2 ) \u2022 hepatic impairment : mild : recommended starting maximum half recommended ( 2.4 ) moderate severe : recommended ( 2.4 ) \u2022 discontinuing sertraline hydrochloride , reduce dose gradually ( 2.6 , 5.4 ) \u2022 oral solution : must diluted ( 2.7 )",
        "doid_entities": [
            {
                "text": "ocd (DOID:84)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_84"
            },
            {
                "text": "ptsd (DOID:2055)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2055"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "sertraline hydrochloride oral solution : clear , colorless solution menthol scent containing sertraline hydrochloride equivalent 20 mg sertraline per ml 12 % alcohol ndc 59762-0067-1 bottles containing 60 ml , accompanying calibrated dropper 25 mg 50 mg graduation marks . store sertraline hydrochloride oral solution 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "sertraline hydrochloride contraindicated patients : \u2022taking , within 14 days stopping , maois , ( including maois linezolid intravenous methylene blue ) increased risk serotonin syndrome [ ( 5.2 ) , ( 7.1 ) ] . \u2022taking pimozide [ ( 7.1 ) ] . \u2022with known hypersensitivity sertraline ( e.g . , anaphylaxis , angioedema ) [ ( 6.1 , 6.2 ) ] . addition sertraline hydrochloride formulations listed , sertraline hydrochloride oral solution contraindicated patients : \u2022taking disulfiram . sertraline hydrochloride oral solution contains alcohol , concomitant sertraline hydrochloride oral solution disulfiram may result disulfiram-alcohol reaction .",
    "indications_original": "Sertraline hydrochloride oral solution is indicated for the treatment of the following [See Clinical Studies (14)]:\n                  \n                     \n                        \u2022Major depressive disorder (MDD)\n                     \n                        \u2022Obsessive-compulsive disorder (OCD)\n                     \n                        \u2022Panic disorder (PD)\n                     \n                        \u2022Posttraumatic stress disorder (PTSD)\n                     \n                        \u2022Social anxiety disorder (SAD)\n                     \n                        \u2022Premenstrual dysphoric disorder (PMDD)",
    "contraindications_original": "Indication Starting Dosage Maximum Dosage MDD ( 2.1 ) 50 mg per day 200 mg per day OCD ( 2.1 ) 25 mg per day (ages 6-12) 50 mg per day (ages \u2265 13) 200 mg per day PD, PTSD, SAD ( 2.1 ) 25 mg per day 200 mg per day PMDD ( 2.2 ) continuous dosing 50 mg per day 150 mg per day PMDD ( 2.2 ) intermittent dosing 50 mg per day during luteal phase only 100 mg per day during luteal phase only \u2022 If inadequate response to starting dosage, titrate in 25-50 mg per day increments once weekly in MDD, OCD, PD, PTSD, and SAD ( 2.1 ) \u2022 See Full Prescribing Information for titration in PMDD ( 2.2 ) \u2022 Hepatic impairment: o Mild: Recommended starting and maximum dosage is half recommended dosage ( 2.4 ) o Moderate or severe: Not recommended ( 2.4 ) \u2022 When discontinuing sertraline hydrochloride, reduce dose gradually ( 2.6 , 5.4 ) \u2022 Oral solution: Must be diluted before administration ( 2.7 )",
    "warningsAndPrecautions_original": "Sertraline Hydrochloride Oral Solution: clear, colorless solution with a menthol scent containing sertraline hydrochloride equivalent to 20 mg of sertraline per mL and 12% alcohol \n                  NDC 59762-0067-1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Bottles containing 60 mL, each with an accompanying calibrated dropper that has 25 mg and 50 mg graduation marks.\n                  Store sertraline hydrochloride oral solution at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [See USP Controlled Room Temperature].",
    "adverseReactions_original": "Sertraline hydrochloride is contraindicated in patients:\n                  \n                     \n                        \u2022Taking, or within 14 days of stopping, MAOIs, (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome [See Warnings and Precautions (5.2), Drug Interactions (7.1)].\n                     \n                        \u2022Taking pimozide [See Drug Interactions (7.1)].\n                     \n                        \u2022With known hypersensitivity to sertraline (e.g., anaphylaxis, angioedema) [See Adverse Reactions (6.1, 6.2)].\n                  \n                  In addition to the contraindications for all sertraline hydrochloride formulations listed above, sertraline hydrochloride oral solution is contraindicated in patients:\n                  \n                     \n                        \u2022Taking disulfiram. Sertraline hydrochloride oral solution contains alcohol, and concomitant use of sertraline hydrochloride oral solution and disulfiram may result in a disulfiram-alcohol reaction.",
    "drug": [
        {
            "name": "Sertraline hydrochloride",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9124"
        }
    ]
}